Sam Brusco, Associate Editor08.29.23
BIOTRONIK announced the first implantation in the U.S. of its Amvia Edge pacemaker, successfully completed by Dr. Raul Weiss at Mount Sinai Medical Center in Miami, Fla.
The Amvia Edge portfolio of pacemakers earned U.S. Food and Drug Administration (FDA) approval in June 2023.
Amvia Edge features MRI Guard 24/7, which according to the company is the market’s only dedicated, always-on MRI sensor. It’s engineered to allow a clinical to greatly reduce the time burden of device management for MRI scans by automatically recognizing when the patient enters an MRI field and converting it to MRI mode. It then automatically returns to its permanent programming after scan completion.
Amvia Edge also touts EarlyCheck, a tool that automates pre-discharge checks. EarlyCheck automatically delivers a device report and IEGM to BIOTRONIKE’s home monitoring service center two hours post-implant so an in-person device interrogation isn’t needed.
"I was very pleased to have been a part of the first implant of Amvia Edge. The procedure went well, and I'm excited about the benefits this new device will be able to bring to our patients as well as our practice," Dr. Weiss told the press. "The ability to eliminate device scans before and after an MRI procedure is a much needed advancement, and I look forward to seeing how these types of technologies help streamline our workflows in the future."
Amvia Edge also has Atrial ATP for multiple, automatic therapies that respond to detected, stable atrial arrhythmias, which according to the company can lower atrial tachycardia burden and help avoid atrial remodeling.
"I'm so pleased to hear about Dr. Weiss and his team's successful first implant of Amvia Edge," said Dr. David Hayes, chief medical officer, BIOTRONIK Inc. "This new family of devices was designed to optimize workflows and therapies to benefit patients and their care teams, as well as clinicians and staff."
The Amvia Edge portfolio of pacemakers earned U.S. Food and Drug Administration (FDA) approval in June 2023.
Amvia Edge features MRI Guard 24/7, which according to the company is the market’s only dedicated, always-on MRI sensor. It’s engineered to allow a clinical to greatly reduce the time burden of device management for MRI scans by automatically recognizing when the patient enters an MRI field and converting it to MRI mode. It then automatically returns to its permanent programming after scan completion.
Amvia Edge also touts EarlyCheck, a tool that automates pre-discharge checks. EarlyCheck automatically delivers a device report and IEGM to BIOTRONIKE’s home monitoring service center two hours post-implant so an in-person device interrogation isn’t needed.
"I was very pleased to have been a part of the first implant of Amvia Edge. The procedure went well, and I'm excited about the benefits this new device will be able to bring to our patients as well as our practice," Dr. Weiss told the press. "The ability to eliminate device scans before and after an MRI procedure is a much needed advancement, and I look forward to seeing how these types of technologies help streamline our workflows in the future."
Amvia Edge also has Atrial ATP for multiple, automatic therapies that respond to detected, stable atrial arrhythmias, which according to the company can lower atrial tachycardia burden and help avoid atrial remodeling.
"I'm so pleased to hear about Dr. Weiss and his team's successful first implant of Amvia Edge," said Dr. David Hayes, chief medical officer, BIOTRONIK Inc. "This new family of devices was designed to optimize workflows and therapies to benefit patients and their care teams, as well as clinicians and staff."